Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
JIB
GLOBETECH PUBLISHING

Pill Appearance Key to Patient Compliance

By BiotechDaily International staff writers
Posted on 31 Jul 2014
Heart attack patients are 30% more likely to discontinue generic cardiovascular medications if their pills change in color or shape, according to a new study.

Researchers at Brigham and Women's Hospital (Boston, MA, USA) conducted cohort and nested case–control studies to determine whether nonpersistent use of generic drugs among 11,513 patients with cardiovascular disease (CVD) after myocardial infarction (MI) is associated with inconsistent appearance of their medications. Study patients were those who discontinued their index medication for at least one month, while control patients continued treatment uninterrupted. Rates of changes in pill color and shape during the year after MI were calculated, and the odds of discordance among case and control patients were compared.

The results showed that 29% of the patients had a change in pill shape or color during the study, correlating with a total of 4, 573 episodes of non-persistence. Statins had the most changes in appearance, whereas β-blockers had the fewest. The researchers found that the odds of nonpersistence in case patients increased by 34% after a change in pill color and 66% after a change in pill shape. Further adjusting the odds ratios for pharmacy changes or use of a mail-order pharmacy did not change the statistically significant associations with nonpersistence, except for color alone. The study was published on July 14, 2014, in Annals of Internal Medicine.

“Some pharmacies do alert patients to changes in medication appearance by placing a sticker on the container. But pill bottles can have so many stickers that the message might be missed,” said lead author Aaron Kesselheim, MD. “Patients need to know that it's common for generics to change their appearance, and that doesn't mean they're working any differently. If patients are concerned by a shift in their medication's shape or color, they should call their doctor or pharmacist rather than just abandoning the drug—even for a short time.”

Currently, the US Food and Drug Administration (FDA) do not interfere with the visual appearance of drugs, which are considered a form of intellectual property. However, the US Supreme Court ruled in 1995 that if the color of a medical pill served a specific function, then competitors were allowed to copy it.

Related Links:

Brigham and Women's Hospital



comments powered by Disqus

Channels

Drug Discovery

view channel

Ibuprofen May Restore Immune Function in Older Individuals

New research suggests that macrophages from the lungs of old mice respond differently to infections than those of young mice, and ibuprofen given to the mice reversed these changes. New research using lab mice suggests that the solution to more youthful immune function might already be a common over-the-counter pain reliever.... Read more

Therapeutics

view channel
Image: Hair follicle (blue) being attacked by T cells (green) (Photo courtesy of Christiano Lab/Columbia University Medical Center).

Hair Restoration Method Clones Patients’ Cells to Grow New Hair Follicles

Researchers have developed of a new hair restoration approach that uses a patient’s cells to grow new hair follicles. In addition, the [US] Food and Drugs Administration (FDA) recently approved a new drug... Read more

Lab Technologies

view channel
Image: Leica Microsystems launches the inverted research microscope platform Leica DMi8 (Photo courtesy of Leica Microsystems).

New Inverted Microscope Designed to Readily Adapt to Changing Research Demands

A new inverted microscope for biotech and other life science laboratories was designed to readily accommodate modifications and upgrades to allow it to keep current with changing research demands and interests.... Read more

Business

view channel

Collaboration of Mayo Clinic and IBM Cognitive Computer Devised to Improve Clinical Trial Research

The Mayo Clinic (Rochester, MN, USA) and IBM (Armonk, NY, USA) recently announced plans to pilot Watson, the IBM cognitive computer, to match patients more rapidly with suitable clinical trials. A proof-of-concept phase is currently ongoing, with the intent to introduce it into clinical use in early 2015.... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.